Immune regulation

a technology of immune regulation and regulation, applied in the field of tissue and organ transplantation, can solve problems such as unreachabl

Inactive Publication Date: 2005-09-01
THE GENERAL HOSPITAL CORP
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0036]“Help reduction”, as used herein, means the reduction of T cell help by the inhibition of the release of at least one cytokine, e.g., any of IL-2, IL-4, IL-6, gamma interferon, or TNF, from T cells of the recipient at the time of the first exposure to an antigen to which graft acceptance is desired. The inhibition induced in a recipient's T cell secretion of a cytokine must be sufficient such that the recipient is tolerized to an antigen which is administered during the reduction of help. Although not being bound by theory, it is believed that the level of reduction is one which substantially eliminates the initial burst of IL-2 which accompanies the first recognition of a foreign antigen but which does not eliminate all mature T cells, which cells may be important in educating and producing graft acceptance.

Problems solved by technology

Broadening the spectrum of potential graft donors, by using donor / recipient pairs matched for class II loci would be highly desirable in clinical transplantation, but unfortunately cannot be achieved due to the extreme structural diversity of class II molecules.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immune regulation
  • Immune regulation
  • Immune regulation

Examples

Experimental program
Comparison scheme
Effect test

example 1

Antibody-Mediated Inhibition of Proliferation of T Cells from Class II-Engineered Animals

[0101] As seen in FIG. 1, the transfer of donor-class II transgenes (Tg) to an animal did not affect the ability of the recipient to respond to the transferred class II proteins through either the direct or indirect pathways.

[0102] (1). Class II transgene introduced. (2). The direct pathway of antigen presentation was assessed with purified T cells from class II engineered animals tested against donor-type irradiated PBLs. The indirect pathway was tested on recipient T cells, supplemented with self APC and stimulated by donor-type irradiated T cells. (3). The combination of anti-DR and -DQ mAbs resulted in 90-100% inhibition in all cases. (4). Not detected. (5). Results from a naïve animal representative of 5 experiments.

Example 2

Expression of Transduced MHC Class II cDNAs in Class II-Committed Cells

[0103] As seen in FIG. 2, flowcytometry analysis of surface protein expression from pig DRA+B...

example 3

MHC class II Peptides Docking onto Self Class II Grooves

[0104] As seen in FIG. 3, computer predictions for potential high affinity class II peptide motifs docking into class II grooves identified mostly autologous Pep2Reg types, for example IA peptides binding preferentially into the IA groove. Furthermore, best fitted class II peptides preferentially derived from polymorphic regions between allelic b chains such as those from the murine IEb 27-57 and IAb 37-54 regions or human DRb1 22-44 (FIG. 3, boxes).

example 4

Flow Cytometry Analysis of CD4 Positive Subsets Stimulated by Autologous Immature DC Cells

[0105] As seen in FIG. 4, results from studies performed in the miniature swine model show that: 1) CD4+, CD25+ T-reg-like cells produced more blasts than their CD4+, CD25neg counterpart following 1 week priming in vitro with syngeneic iDC (CD1neg, CD2neg, CD3neg, Monocytepos, class IIpos), (FIG. 4, R3 gate); 2) T-reg-like cells also expressed marker of activation such as CTLA4 (FIG. 4, lower right panel).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to view more

Abstract

A method of regulating the immune system of a subject that involves removing antigen presenting cells from subject and loading preselected class II peptide fragments onto the subjects APC's outside the body of the subject.

Description

RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Provisional Application Ser. No. 60 / 361,136, filed Mar. 1, 2002, the contents of which are incorporated herein by reference in their entirety.TECHNICAL FIELD [0002] This invention relates to tissue and organ transplantation. BACKGROUND [0003] Since their discovery, the function of MHC class II genes has been associated with immune regulations. Although conclusions drawn from structural studies on class II heterodimers have primarily confined their role to that of presentation of antigenic peptides along with the class I molecules, numerous studies have indicated that class II proteins and / or their processed peptides should not only be regarded as histocompatibility antigens, i.e. targets of immune reactions. [0004] The development of numerous autoimmune diseases is associated with particular class II alleles although the specific implication of these class II alleles on either the presentation of self-antigenic ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A01N63/00A61BA61K39/395A61K45/00C07K16/28C12N5/0784
CPCA61K2039/5154A61K2039/5158C07K16/2833A61K45/06C12N5/0639A61K39/001C07K2316/96C07K2317/73A61P7/00
Inventor LEGUERN, CHRISTIAN A.
Owner THE GENERAL HOSPITAL CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap